Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Impact of aspirin dose on adenosine diphosphate-mediated platelet activities. Results of an in vitro pilot investigation.

Tello-Montoliu A, Thano E, Rollini F, Patel R, Wilson RE, Muñiz-Lozano A, Franchi F, Darlington A, Desai B, Guzman LA, Bass TA, Angiolillo DJ.

Thromb Haemost. 2013 Oct;110(4):777-84. doi: 10.1160/TH13-05-0400. Epub 2013 Jul 25.

PMID:
23884248
2.

Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease.

Darlington A, Tello-Montoliu A, Rollini F, Ueno M, Ferreiro JL, Patel R, Desai B, Guzman LA, Bass TA, Angiolillo DJ.

Thromb Haemost. 2014 Feb;111(2):258-65. doi: 10.1160/TH13-07-0529. Epub 2013 Oct 24.

PMID:
24154863
3.

Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients.

Rollini F, Franchi F, Tello-Montoliu A, Patel R, Darlington A, Ferreiro JL, Cho JR, Muñiz-Lozano A, Desai B, Zenni MM, Guzman LA, Bass TA, Angiolillo DJ.

JACC Cardiovasc Interv. 2014 Apr;7(4):426-34. doi: 10.1016/j.jcin.2013.11.019. Epub 2014 Mar 13.

4.

Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy: Results From a Prospective, Randomized, Double-Blind Investigation.

Cho JR, Rollini F, Franchi F, DeGroat C, Bhatti M, Dunn EC, Ferrante E, Muniz-Lozano A, Suryadevara S, Zenni MM, Guzman LA, Bass TA, Angiolillo DJ.

JACC Cardiovasc Interv. 2015 Jul;8(8):1075-83. doi: 10.1016/j.jcin.2015.02.022. Epub 2015 Jun 24.

5.

Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation.

Rollini F, Tello-Montoliu A, Patel R, Darlington A, Wilson RE, Franchi F, Muñiz-Lozano A, Desai B, Bender N, Sakariassen KS, Angiolillo DJ.

J Thromb Thrombolysis. 2014;37(2):131-8. doi: 10.1007/s11239-013-0979-8.

PMID:
23943337
6.

Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel.

Bouman HJ, Parlak E, van Werkum JW, Breet NJ, ten Cate H, Hackeng CM, ten Berg JM, Taubert D.

J Thromb Haemost. 2010 Mar;8(3):482-8. doi: 10.1111/j.1538-7836.2009.03733.x. Epub 2009 Dec 21.

7.

Response to antiplatelet therapy is independent of endogenous thrombin generation potential.

Gremmel T, Panzer S, Steiner S, Seidinger D, Koppensteiner R, Pabinger I, Kopp CW, Ay C.

Thromb Res. 2013 Jul;132(1):e24-30. doi: 10.1016/j.thromres.2013.04.008. Epub 2013 Apr 25.

PMID:
23623170
8.

Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease.

Angiolillo DJ, Jakubowski JA, Ferreiro JL, Tello-Montoliu A, Rollini F, Franchi F, Ueno M, Darlington A, Desai B, Moser BA, Sugidachi A, Guzman LA, Bass TA.

J Am Coll Cardiol. 2014 Sep 9;64(10):1005-14. doi: 10.1016/j.jacc.2014.06.1170.

9.

Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition.

Aradi D, Magyarlaki T, Tokés-Füzesi M, Rideg O, Vorobcsuk A, Komócsi A.

Platelets. 2010;21(7):563-70. doi: 10.3109/09537104.2010.494742.

PMID:
20642320
10.

Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic Investigation.

Franchi F, Rollini F, Cho JR, Bhatti M, DeGroat C, Ferrante E, Dunn EC, Nanavati A, Carraway E, Suryadevara S, Zenni MM, Guzman LA, Bass TA, Angiolillo DJ.

JACC Cardiovasc Interv. 2015 Sep;8(11):1457-67. doi: 10.1016/j.jcin.2015.02.030.

11.

Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin.

Liang Y, Johnston M, Hirsh J, Pare G, Li C, Mehta S, Teo KK, Sloane D, Yi Q, Zhu J, Eikelboom JW.

J Thromb Thrombolysis. 2012 Nov;34(4):429-36. doi: 10.1007/s11239-012-0762-2. Erratum in: J Thromb Thrombolysis. 2013 Jan;35(1):130.

PMID:
22797934
12.

Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel.

Ueno M, Ferreiro JL, Tomasello SD, Tello-Montoliu A, Capodanno D, Seecheran N, Kodali M, Dharmashankar K, Desai B, Charlton RK, Bass TA, Angiolillo DJ.

JACC Cardiovasc Interv. 2011 Aug;4(8):905-12. doi: 10.1016/j.jcin.2011.05.016.

13.

Nuisance and alarming bleeding do not correlate with on-treatment platelet reactivity.

Gaglia MA Jr, Torguson R, Pokharel S, Pakala R, Xue Z, Suddath WO, Kent KM, Satler LF, Pichard AD, Waksman R.

Cardiovasc Revasc Med. 2013 Mar-Apr;14(2):76-80. doi: 10.1016/j.carrev.2012.12.005. Epub 2013 Jan 31.

PMID:
23375617
14.

Comparison of the VASP assay and platelet aggregometry in the evaluation of platelet P2Y12 receptor blockade.

Kuliczkowski W, Rychlik B, Chiżyński K, Watała C, Golański J.

Pol Arch Med Wewn. 2011 Apr;121(4):115-21.

15.

Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading.

Kim IS, Jeong YH, Tantry US, Park Y, Lee DH, Bliden KP, Koh JS, Park JR, Jang JS, Hwang SJ, Koh EH, Kwak CH, Hwang JY, Kim S, Gurbel PA.

Am Heart J. 2013 Jul;166(1):95-103. doi: 10.1016/j.ahj.2013.03.030. Epub 2013 May 6.

PMID:
23816027
16.
17.

P2Y12 polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease.

Bierend A, Rau T, Maas R, Schwedhelm E, Böger RH.

Br J Clin Pharmacol. 2008 Apr;65(4):540-7. Epub 2007 Nov 8.

18.

Comparison of a new ELISA assay with the flow cytometric assay for platelet vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation in whole blood to assess P2Y(12) inhibition.

Jakubowski JA, Bourguet N, Boulay-Moine D, Sugidachi A, Yamaguchi S, Barragan P, Zhou C, Moulard M.

Thromb Haemost. 2012 Feb;107(2):388-95. doi: 10.1160/TH11-04-0282. Epub 2011 Dec 21.

PMID:
22186965
19.

The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent.

Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.

Thromb Res. 2011 Oct;128(4):352-7. doi: 10.1016/j.thromres.2011.05.008. Epub 2011 May 28.

PMID:
21621250
20.

Comparison of antiplatelet effects of prasugrel and ticagrelor in cynomolgus monkeys by an ELISA-based VASP phosphorylation assay and platelet aggregation.

Tomizawa A, Ohno K, Jakubowski JA, Mizuno M, Sugidachi A.

Thromb Haemost. 2013 Oct;110(4):769-76. doi: 10.1160/TH13-03-0260. Epub 2013 Aug 1.

PMID:
23903326

Supplemental Content

Support Center